Clinical trial

Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer

NCT04489940

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2020-10-12

PhasePHASE2

Study timeline

Study start (actual)2020-10-12Date precision: day

Registry last updated2023-04-10

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Triple Negative Breast Neoplasmsunresolved

Interventions

Bintrafusp alfaDRUG

Sponsors & collaborators

EMD Serono Research & Development Institute, Inc.lead sponsor

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germanycollaborator

Mapped research locations

MadridSpain3 MilanItaly2 DallasTexas, United States1 San AntonioTexas, United States1 ParisFrance1 ColumbusOhio, United States1 JacksonvilleFlorida, United States1 AustinTexas, United States1 CharlestonSouth Carolina, United States1 MoscowRussia1 Saint PetersburgRussia1 SevilleSpain1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04489940 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.